IBRUTINIB PLUS PALBOCICLIB HAS EFFICACY IN MANTLE CELL LYMPHOMA

被引：0
|
作者：
不详
机构：
来源：
CANCER DISCOVERY | 2019年 / 9卷 / 03期
关键词：
D O I：
10.1158/2159-8290.CD-RW2019-016
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
The BTK inhibitor ibrutinib plus the CDK4 inhibitor palbociclib achieves responses in 67% of MCL patients. © 2019 American Association for Cancer Research.
引用
收藏
页码：318 / 318
页数：1
相关论文
共 50 条
  • [1] A phase 1 trial of ibrutinib plus palbociclib in previously treated mantle cell lymphoma
    Martin, Peter
    Bartlett, Nancy L.
    Blum, Kristie A.
    Park, Steven
    Maddocks, Kami
    Ruan, Jia
    Ridling, Leann
    Dittus, Christopher
    Chen, Zhengming
    Huang, Xiangao
    Inghirami, Giorgio
    DiLiberto, Maurizio
    Chen-Kiang, Selina
    Leonard, John P.
    BLOOD, 2019, 133 (11) : 1201 - 1204
  • [2] A Phase I Trial of Ibrutinib Plus Palbociclib in Patients with Previously Treated Mantle Cell Lymphoma
    Martin, Peter
    Blum, Kristie
    Bartlett, Nancy L.
    Park, Steven I.
    Maddocks, Kami J.
    Ruan, Jia
    Di Liberto, Maurizio
    Huang, Xiangao
    Inghirami, Giorgio
    Harris, Pamela
    Chen-Kiang, Selina
    Leonard, John P.
    BLOOD, 2016, 128 (22)
  • [3] Ibrutinib plus Venetoclax for the Treatment of Mantle-Cell Lymphoma
    Tam, Constantine S.
    Anderson, Mary Ann
    Pott, Christiane
    Agarwal, Rishu
    Handunnetti, Sasanka
    Hicks, Rodney J.
    Burbury, Kate
    Turner, Gillian
    Di Iulio, Juliana
    Bressel, Mathias
    Westerman, David
    Lade, Stephen
    Dreyling, Martin
    Dawson, Sarah-Jane
    Dawson, Mark A.
    Seymour, John F.
    Roberts, Andrew W.
    NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (13): : 1211 - 1223
  • [4] Ibrutinib for mantle cell lymphoma
    Tucker, David L.
    Rule, Simon A.
    FUTURE ONCOLOGY, 2016, 12 (04) : 477 - 491
  • [5] A phase 1 trial of ibrutinib plus palbociclib in previously treated mantle cell lymphoma (vol 133, pg 1201, 2019)
    Martin, P.
    Bartlett, N. L.
    Blum, K. A.
    BLOOD, 2019, 134 (11) : 908 - 908
  • [6] Ibrutinib plus Bendamustine and Rituximab in Untreated Mantle-Cell Lymphoma
    Wang, Michael L.
    Jurczak, Wojciech
    Jerkeman, Mats
    Trotman, Judith
    Zinzani, Pier L.
    Belada, David
    Boccomini, Carola
    Flinn, Ian W.
    Giri, Pratyush
    Goy, Andre
    Hamlin, Paul A.
    Hermine, Olivier
    Hernandez-Rivas, Jose-Angel
    Hong, Xiaonan
    Kim, Seok Jin
    Lewis, David
    Mishima, Yuko
    Ozcan, Muhit
    Perini, Guilherme F.
    Pocock, Christopher
    Song, Yuqin
    Spurgeon, Stephen E.
    Storring, John M.
    Walewski, Jan
    Zhu, Jun
    Qin, Rui
    Henninger, Todd
    Deshpande, Sanjay
    Howes, Angela
    Le Gouill, Steven
    Dreyling, Martin
    NEW ENGLAND JOURNAL OF MEDICINE, 2022, 386 (26): : 2482 - 2494
  • [7] A Novel Triplet of Alisertib Plus Ibrutinib Plus Rituximab Is Active in Mantle Cell Lymphoma
    Subramani, Baskaran
    Conway, Patrick J.
    Al-Khinji, Aisha
    Zhang, Kun
    Pandey, Ritu
    Mahadevan, Daruka
    CANCERS, 2024, 16 (24)
  • [8] Ibrutinib for the treatment of mantle cell lymphoma
    Shah, Nimish
    Hutchinson, Claire
    Rule, Simon
    EXPERT REVIEW OF HEMATOLOGY, 2014, 7 (05) : 521 - 531
  • [9] Ibrutinib for the Treatment of Mantle Cell Lymphoma
    Herrera, Alex F.
    Jacobsen, Eric D.
    CLINICAL CANCER RESEARCH, 2014, 20 (21) : 5365 - 5371
  • [10] Ibrutinib, Venetoclax Plus Obinutuzumab in Newly Diagnosed Mantle Cell Lymphoma Patients
    Le Gouill, Steven
    Morschhauser, Franck
    Bouabdallah, Kamal
    Cartron, Guillaume
    Casasnovas, Olivier
    Gastinne, Thomas
    Chevallier, Patrice
    Rossi, Cedric
    Tchernonog, Emmanuelle
    McCulloch, Rory
    Herbaux, Charles
    Chiron, David
    Callanan, Mary
    Rule, Simon
    BLOOD, 2019, 134
12345